Page 8 - Phissons Ethics Dilemma
P. 8

Projections




                                                                 Sales projections indicated that by year

                                                                 three all sunk costs will have been


                                                                 recovered. Thereafter profit momentum

                                                                 would be maintained as Proxydychromil


                                                                 is introduced into new markets especially

                                                                 the US and Canada. This will be followed


                                                                 by introductions into other developed

                                                                 markets.






                                                                             If Phissons withdraws the


                                                                             drug before the launch the

                                                                             impact will be catastrophic.


                                                                             The fear is that the share

                                                                             price will collapse as


                                                                             investors seek to minimise

                                                                             their risk exposure.







               The alternative is to launch the drug and bear the fallout from the inevitable deaths.
   3   4   5   6   7   8   9   10   11   12   13